Fakih, M., Segal, N. H., Schlechter, B. L., André, T., Pietrantonio, F., Johnson, B., Vasilyev, A., Krishnamurthi, S. S., Siena, S., Messersmith, W. A., Silva, V. S. E., Paulson, A. S., Elez, E., Eng, C., Tejpar, S., Ducreux, M. P., Wu, W., Grossman, J. E., Cutsem, E. V., Hidalgo, M. (2025). Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.23